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INTRODUCTION:  Primary  pancreatic  neuroendocrine  tumors  are  a well-established  disease  entity,  how-
ever,  neuroendocrine  metastases  to the pancreas  from  other  sites  have  been  scarcely  documented.
Speciﬁcally,  pancreatic  metastases  from  a pulmonary  carcinoid  tumor  have  only previously  been
described  in  a single  case  report.
PRESENTATION  OF  CASE:  We  sought  to outline  our  institutional  experience  of  two  patients  with  pul-
monary  neuroendocrine  tumors  that  developed  metastases  to the  pancreas,  conﬁrmed  by gross  pathology
and immunohistochemistry.  In  both  cases,  the  pancreatic  metastases  were  surgically  resected  and  their
pulmonary  origin  were  discovered  post-operatively.
DISCUSSION:  Our  ﬁndings  should  raise  awareness  to the  possibility  of metastatic  disease  when  evaluating
a  pancreatic  mass  in  a patient  with  a clinical  history  of  pulmonary  carcinoid  tumor.  Expert  opinion  on
immunohistochemically  differentiating  a primary  pancreatic  neuroendocrine  malignancy  from  a  metas-
tasis should  be employed  in these  cases.
CONCLUSION:  Establishing  this  diagnosis  pre-operatively  could  affect  the  decision  to proceed  with  sur-
gical resection,  given  the  morbidity  of  pancreatectomy  and  the  unknown  long-term  clinical  outcome  of
patients  with  pulmonary  carcinoid  tumors  metastatic  to  the  pancreas.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
Neuroendocrine tumors (NETs) of the pancreas are rare, com-
rising 1–2% of all pancreatic malignancies.1 The vast majority of
hese are primary pancreatic malignancies, as metastases to the
ancreas are rare, and metastases of neuroendocrine tumors from
ther primary sources to the pancreas are even rarer.
Pulmonary neuroendocrine tumors comprise 20–30% of all NETs
nd 11–14% of all lung cancers and are classiﬁed into four sub-
ypes, typical and atypical carcinoid, small cell lung carcinoma and
arge cell neuroendocrine carcinoma.2,3 Depending on their degree
f differentiation, these tumors have been well-documented to
etastasize to intrathoracic lymph nodes, liver, central nervous
ystem (CNS), skeletal bones, adrenals, and mammary glands.3
here are reports of pulmonary NETs rarely metastasizing to other
are locations. For example, Birker et al.4 published a case report
f a metastasis to the testis from a primary NET of the lung.
hoi et al.5 showed in a case report that atypical lung NETs in an
∗ Corresponding author at: The Johns Hopkins Hospital, 600 N. Wolfe Street, Hal-
ted 608, Baltimore, MD,  USA. Tel.: +1 410 614 3368; fax: +1 410 614 9493.
E-mail address: mweiss5@jhmi.edu (M.J. Weiss).
ttp://dx.doi.org/10.1016/j.ijscr.2014.03.021
210-2612/© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical A
http://creativecommons.org/licenses/by-nc-nd/3.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
asymptomatic patient can metastasize to the breast. We  have only
found one other case of metastatic NET to the pancreas arising from
the lung in the literature.6
Similarly, in studies of carcinomas metastatic to the pancreas,
pulmonary origin is rare. In an autopsy study of 1740 Japanese
patients with 690 malignant tumors of non-primary pancreatic ori-
gin, Nakamura et al.7 found only 103 secondary pancreatic tumors,
17% of which originated from the lung, and none of which were
NETs. Kim et al.8 performed a review of 371 patients with NETs
from various sites, in which none of the pancreatic NETs had their
origin in the lung.
2. Presentation of cases
2.1. Case report 1
A 58-year-old female presented to our clinic in June 2013 with
an incidentally diagnosed pancreatic neuroendocrine tumor. She
was previously enrolled in a clinical trial in 2011 for low dose
Computed Tomography (CT) surveillance protocol for lung cancer.
At that time, she was  found to have a 1.4 cm carcinoid tumor of
the right lung. She denied having carcinoid symptoms at the time,
with the exception of occasional diarrhea. Reportedly, her urine
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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-hydroxyindoleacetic acid (5-HIAA) was within normal limits. Of
ote, a somatostatin receptor scintigraphy performed at the time
as negative. She underwent a thoracotomy with lobar resection
f the carcinoid tumor, with post-operative follow-up CT scans at
-month intervals. On the last scheduled surveillance in June 2013,
n incidental 1 cm pancreatic tail mass was discovered. Endoscopic
ltrasound (EUS) with biopsy of the tumor was performed with
ndings consistent with a pancreatic neuroendocrine tumor. The
atient denied any symptoms suggestive of hormonal secretion by
he tumor. A gallium scan was negative, though a positron emis-
ion tomography (PET) scan demonstrated increased uptake in the
umor area. A CT scan in our institution revealed a 3.4 cm × 2.1 cm
rea of hypoattenuation in the pancreatic tail, best visualized on
he arterial phase images, corresponding to the patient’s recent
US and biopsy proven neuroendocrine tumor in the pancreatic tail
Fig. 1). Interestingly, the mass itself demonstrated no appreciable
nternal hypervascularity on the arterial phase, and moreover, it
as relatively poorly deﬁned. In addition, there was no evidence of
istant metastatic disease or any suspicious lymphadenopathy.
The patient’s medical history was otherwise only notable for
reast cancer in 2001 and hypertriglyceridemia. The decision was
ade with the patient’s involvement, to have this mass surgically
esected, and a distal pancreatectomy and splenectomy was per-
ormed.
The surgical pathology results demonstrated a neuroendocrine
arcinoma (WHO grade 3), 1.9 cm in size, involving the pancreas
nd the peripancreatic tissue (Fig. 2). Multiple foci of vascular
nd perineural invasion were identiﬁed. Background pancreas
howed pancreatic intraepithelial neoplasia, and twenty-three
ymph nodes that were taken were negative for tumor. This neu-
oendocrine tumor in the pancreas was morphologically similar
o the patient’s previous lung tumor. The neoplastic cells in the
ancreas immunolabeled with antibodies to synaptophysin and
hromogranin and were negative for TTF1 and PAX8, with a high
i67 index of nearly 25%.
The pathology from the patient’s right lower lobe lung mass was
eviewed, and it demonstrated atypical carcinoid (Grade 2 well-
ifferentiated neuroendocrine neoplasm) measuring 1.4 cm with
ymphovascular invasion. Focal necrosis was observed and up to
ve mitoses per 10 high power ﬁelds were identiﬁed. Resection
argins were negative for the tumor. Submitted immunostainshowed the neoplastic cells to be focally positive for TTF-1 and
egative for CDX-2 and PAX-8, and a Ki-67 proliferation index of 8%.
To ensure that the lung was the primary source for the pancre-
tic NET, we had to rule out a metastasis from the patient’s previous
ig. 1. IV-contrast enhanced arterial phase abdominal CT scan (Case 1) demonstrat-
ng 1.5 cm × 1.1 cm × 1.5 cm mass at the pancreatic tail (arrow).Fig. 2. Gross specimen of the pancreatic tail (Case 1) demonstrating a
1.7  cm × 1.9 cm lesion (arrow) at the periphery 2.0 mm from the pancreatic duct.
breast cancer. A panel of breast cancer immunomarkers applied to
the tumor in the pancreas demonstrated positive immunostaining
for CK7, while stains for ER, PR, CK20, GATA-3, GCDFP and mam-
moglobin were all negative. This pattern suggests against a breast
primary. Given the similar morphology and otherwise identical
immunolabeling proﬁles, we  would strongly favor that the lesion
in the pancreas is a metastasis from the patient’s previous lung
atypical carcinoid tumor.
2.2. Case report 2
The second case is a 59-year-old female of Ashkenazi descent,
who was diagnosed with small cell lung cancer in 2003. Of note, the
patient is germline BRCA2 mutation carrier. At that time, she was
treated with a cisplatin-based chemotherapy regimen, lung irra-
diation, and partial prophylactic radiation to the brain at another
hospital. In 2006, she was  also diagnosed with Stage IIIC serous
adenocarcinoma of the ovary, which was surgically managed and
followed with 6 cycles of taxol and carboplatin chemotherapy. In
subsequent follow-up, a rise in her CA-125 was  noted, however,
imaging studies have failed to demonstrate a deﬁnitive ovarian can-
cer recurrence. Imaging revealed an abnormality in the tail of the
pancreas, and a positron emission tomography (PET) scan demon-
strated uptake in this area. An endoscopic ultrasound and biopsy of
this pancreatic tail lesion demonstrated neoplastic cells consistent
with either a new primary or possibly metastatic disease from the
lung.
A distal pancreatectomy, splenectomy, and paraortic lym-
phadenectomy were performed. Surgical pathology showed atyp-
ical neuroendocrine neoplasm, most consistent with a metastatic
atypical carcinoid tumor, 2.5 cm in size, involving the parenchyma
of the pancreas. Metastatic atypical neuroendocrine neoplasm was
present in three of seventeen lymph nodes. Spleen and all mar-
gins were negative for tumor. The lesion was  composed of spindle
shaped neuroendocrine cells with an increased mitotic rate, which
focally reached the threshold for atypical carcinoid (5–20 mitoses
per 20 hpf). A panel of immunostains was  performed, and the
neoplasm in the pancreas was  strongly positive for cytokeratin
AE1/AE3, synaptophysin and chromogranin. While it was also posi-
tive labeling for somatostatin, this stain is known to have a very high
background and it is challenging to identify how much of this label-
ing is speciﬁc. The neoplasm also weakly immunolabelled for TTF-1
and demonstrated a sustentacular pattern of labeling for S-100 pro-
tein. Stains for Ki-67 labeled approximately 5% of the neoplastic
cells. Stains for insulin and glucagon were negative. This pattern
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f labeling is most certainly consistent with an atypical carcinoid
umor of the lung metastatic to the pancreas.
. Discussion
Our two cases establish the possibility of lung neuroendocrine
umors metastasizing to the pancreas, even years after the diag-
osis of the primary lung tumor. Clinicians should consider this
ossibility when evaluating newly discovered pancreatic masses
n patients with a history of lung neuroendocrine neoplasms.
n our experience, endoscopic ultrasound with ﬁne needle aspi-
ation should be instrumental in the diagnostic evaluation of
hese patients, when technically feasible. Obtaining tissue diagno-
is enables the comparison of the pancreatic mass’s morphologic
haracteristics and immunohistochemical proﬁle to those of the
revious lung NET. In particular, immunohistochemistry plays a
ital role in differentiating primary pancreatic NET versus neuroen-
ocrine metastasis and expert opinion on choosing and interpreting
mmunohistochemical markers should be sought. While the man-
gement of primary pancreatic neuroendocrine tumors is well
utlined, there is scarcity of data on long-term outcomes of pan-
reatic neuroendocrine metastases from the lung.
Therefore, establishing this diagnosis pre-operatively could be
nstrumental in the treatment decision-making. Although surgical
esection of the metastases was feasible in both of our cases and
s likely to be technically feasible in the majority of similar cases
n the absence of widespread disease, there are no published data
escribing long-term outcomes following resection of pulmonary
euroendocrine metastases to the pancreas. By deﬁnition, patients
ith lung NET metastases to the pancreas have systemic disease
ith likely micro-metastases present, but not yet clinically evident,
n other organs. Therefore, the beneﬁt of metastasectomy via pan-
reatectomy in this setting remains to be deﬁned. Furthermore, the
iming and choice of chemotherapy in this patient population is
nclear.
4. Conclusion
In conclusion, these two  cases highlight that metastases to
the pancreas from lung NET are possible, although they remain
very rare. Clinicians should be aware of this possibility during the
follow-up of patients with a history of lung NET. Furthermore,
our case reports identiﬁes the subtleties of diagnosis and manage-
ment in those patients and highlights that expert opinion should be
sou
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Key learning points
• Neuroendocrine tumors of the lung can metastasize to the pancreas.
• Tissue biopsy by EUS and immunohistochemical staining is paramount in differentiating primary neuroendocrine
tumors of the pancreas from neuroendocrine metastasis.
• Expert opinion should be sought if neuroendocrine metastasis to the pancreas is suspected.
• The value of pancreatectomy for neuroendocrine metastasis to the pancreas remains unclear.
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